Pharmacists' anticipated pain compared to experienced pain associated with insulin pen injection and fingertip lancing

Canadian Journal of Diabetes

Volumn 35, Issue 3, 2011, Pages 282-286

  Diamond, Shelley A ^a   Matok, Ilan ^b  

^a Pedipharm Consultants   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Blood glucose monitoring; Diabetes; Injection; Insulin; Pain

Indexed keywords

INSULIN;

ANTICIPATION; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; FINGERTIP LANCING; GLUCOSE TOLERANCE TEST; HUMAN; INJECTION PAIN; MEDICAL EDUCATION; MEDICAL PRACTICE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN ASSESSMENT; PHARMACIST; VISUAL ANALOG SCALE;

EID: 79960944042     PISSN: 14992671     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-2671(11)53012-6     Document Type: Article

References (20)

1. Harris SB, Ekoé JM, Zdanowicz Y, et al. Glycemic control and morbidity in the Canadian primary care setting (results of the Diabetes In Canada Evaluation study). Diabetes Res Clin Pract, 2005;70:90-97.
2. McCrate F, Godwin M, Murphy L. Attainment of Canadian Diabetes Association recommended targets in patients with type 2 diabetes: A study of primary care practices in St. John's, Nfld. Can Fam Physician, 2010;56:e13-e19.
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prosepective Diabetes Study (UKPDS) Group. Lancet, 1998;352:837-853.
4. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract, 1995;28:103-117.
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 1993;329:977-986.
6. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes, 2008;32(suppl 2):S1-S201.
7. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med, 2008;359:1577-1589.
8. Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in newly diagnosed type 2 diabetes: A multicentre randomised parallel-group trial. Lancet, 2008;371:1753-1760.
9. Houlden R, Ross S, Harris S, et al. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of type 2 diabetes: The Canadian INSIGHT Study. Diabetes Res Clin Pract, 2007;78:254-258.
10. Nakar S, Yitzhaki G, Rosenberg R, et al. Transition to insulin in type 2 diabetes: Family physicians' misconception of patients' fears contributes to existing barriers. J Diabetes Complications, 2007;21:220-226.
11. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: The scope of the problem. Diabetes Care, 2005;28:2543-2545.
12. Haque M, Emerson SH, Dennison CR, et al. Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Cape Town. S Afr Med J, 2005;95:798-802.
13. Peyrot M, Rubin RR, Lauritzen T, et al; International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: Results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care, 2005;28:2673-2679.
14. Larkin ME, Capasso VA, Chen CL, et al. Measuring psychological insulin resistance: Barriers to insulin use. Diabetes Educ, 2008;34:511-517.
15. Fu AZ, Qiu Y, Radican L. Impact of fear of insulin or fear of injection on treatment outcomes of patients with diabetes. Curr Med Res Opin, 2009;25:1413-1420.
16. Kroon LA, Coleman LT, Koda-Kimble MA. The management of type 2 diabetes mellitus: A call to action for pharmacists. US Pharmacist, 1997;(suppl 1):1-18.
17. Campbell RK. DCCT opens new opportunities for pharmacists. California Pharmacist, 1993;Dec:26-27.
18. Ramalho de Oliveira D, Brummel AR, Miller DB. Medication therapy management: 10 years of experience in a large integrated health care system. J Manag Care Pharm, 2010;16:185-195.
19. Cranor CW, Bunting BA, Christensen DB. The Asheville Project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc (Wash), 2003;43:173-184.
20. Karter AJ, Subramanian U, Saha C, et al. Barriers to insulin initiation: The translating research into action for diabetes insulin starts project. Diabetes Care, 2010;33:733-735.